Inizio vs Veeva

Inizio wins 4 silver awards at the 2026 Brandon Hall Group HCM Excellence Awards

Inizio's Leader and Manager Accelerator Program and AI Academy has received four silver awards at the 2026 HCM Excellence Awards®.

Inizio Medical celebrates two MM+M Award finalist nominations for AI innovation in Medical Affairs

Inizio Medical has been named a finalist in two categories at the 2026 MM+M Awards, recognizing collaborations with...

New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day

Veeva announces a new Study Builder Agent that can configure clinical studies in as little as one day, along with other updates including another Top 20 biopharma choosing Vault CRM and the introduction of Falcon Router for agentic triage.

Stop Anthropomorphizing LLMs, Treat Them as Tools

This article argues that marketers and tech professionals fundamentally misunderstand large language models (LLMs) by treating them as conscious entities. It explains that LLMs are statistical pattern engines that predict the next token based on probability, not logical reasoning. This leads to common failures like miscounting letters or clinging to incorrect answers. The author advises abandoning implicit logic by breaking tasks into single steps, providing tight constraints to reduce hallucinations, and not arguing with erroneous outputs. By reframing LLMs as tools rather than coworkers, marketing workflows can be made more effective and efficient.

• LLMs are predictive text engines based on statistical probability, not human logic.
• LLMs break text into tokens, which can obscure letter-level details and cause miscounting.
• Users should break tasks into single-purpose steps to improve LLM output accuracy.

10-Q Financial Filing Analysis for Veeva (2026-08-27)

Veeva Systems Inc. reported strong financial results for the second quarter of fiscal year 2027 ended July 31, 2026, with total revenue rising 18% year-over-year to $927.96 million. Top-line expansion was driven by a 16% increase in core subscription revenues to $766.76 million alongside a 24% rise in professional services to $161.20 million, driving GAAP operating income up to $275.02 million from $195.91 million in Q2 FY2026. Operationally, Veeva advanced its major migration of CRM customers from Salesforce to its proprietary Vault CRM platform (supported through 2029) and integrated Rise Healthcare Tech (Ostro), an AI-driven engagement platform acquired for $90 million, while deploying $246 million toward share repurchases.

• Q2 FY2027 total revenue grew 18% YoY to $927.96 million, led by $766.76 million in subscription revenue and $161.20 million in professional services, yielding a GAAP operating income of $275.02 million.
• The strategic migration from Salesforce to the proprietary Vault CRM platform continues ahead of the December 31, 2029 support deadline.
• Capital allocation included the $90 million ($70 million net of cash) acquisition of AI engagement platform Rise Healthcare Tech (Ostro) and the repurchase of 1,408,414 shares of common stock for approximately $246 million.